Voyager Acquisition Corp. (VACH)
| Market Cap | 406.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 8.99M |
| Shares Out | 31.63M |
| EPS (ttm) | 0.28 |
| PE Ratio | 46.26 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,637 |
| Open | 12.95 |
| Previous Close | 13.15 |
| Day's Range | 12.80 - 13.14 |
| 52-Week Range | 8.81 - 15.68 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VACH
Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. Voyager Acquisition Corp. was incorporated in 2023 and is based in Brooklyn, New York. [Read more]
News
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) held the general meeting on March 12, 2026 and approv...
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Com...
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequisites for the closing of the business combination.
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
Partnership combines Secarna's OligoCreator® platform with VERAXA's technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases Partnership combines Secarna'...
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempt...
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with...
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel...